Tom John
Impact in
- Pulmonary and Respiratory Medicine top 0.1%
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- Occupational and environmental lung diseases
- Oncology top 0.2%
- Lung Cancer Research Studies
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Treatments and Studies
Papers in
-
- Lung Cancer Treatments and Mutations 91
- Occupational and environmental lung diseases 24
- Lung Cancer Diagnosis and Treatment 21
- Oncology 98
- Cancer Immunotherapy and Biomarkers 42
- Lung Cancer Research Studies 28
- Colorectal Cancer Treatments and Studies 23
- Co-authors
- Frances Alice Shepherd (16 shared papers)Alexander Dobrovic (12 shared papers)Puey Ling Chia (12 shared papers)Ming‐Sound Tsao (9 shared papers)Suresh S. Ramalingam (7 shared papers)Geoffrey Liu (4 shared papers)Paul Leslie Ross Mitchell (12 shared papers)Yi-Long Lung Cancer Wu (16 shared papers)
- Journals
- Journal of Thoracic Oncology (31 papers)Annals of Oncology (23 papers)Lung Cancer (13 papers)Translational Lung Cancer Research (11 papers)Journal of Clinical Oncology (8 papers)
- Partner nations
- AustraliaUnited StatesUnited Kingdom
In The Last Decade
Tom John
243 papers receiving 13.9k citations
Tom John's Hit Papers
Peers
Comparison fields: 5 of 143
- Pulmonary and Respiratory Medicine 7.8k
- Oncology 5.9k
- Cancer Research 1.9k
- Ophthalmology 395
- Pathology and Forensic Medicine 765
Countries citing papers authored by Tom John
This map shows the geographic impact of Tom John's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tom John with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tom John more than expected).
Fields of papers citing papers by Tom John
This network shows the impact of papers produced by Tom John. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tom John. The network helps show where Tom John may publish in the future.
Co-authors
The 25 scholars most cited alongside Tom John, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 257 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Overall Survival with Osimertinib in Untreated, EGFR -Mutated Advanced NSCLC Hit paper breakdown → | 2019 | 2202 |
| 2 | Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials Hit paper breakdown → | 2019 | 1330 |
| 3 | Osimertinib in Resected EGFR -Mutated Non–Small-Cell Lung Cancer Hit paper breakdown → | 2020 | 1288 |
| 4 | First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial Hit paper breakdown → | 2021 | 1061 |
| 5 | Osimertinib As First-Line Treatment of EGFR Mutation–Positive Advanced Non–Small-Cell Lung Cancer Hit paper breakdown → | 2017 | 453 |
| 6 | Overall Survival with Osimertinib in Resected EGFR -Mutated NSCLC Hit paper breakdown → | 2023 | 402 |
| 7 | Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials Hit paper breakdown → | 2019 | 398 |
| 8 | Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non–Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial Hit paper breakdown → | 2023 | 256 |
| 9 | 2020 | 216 | |
| 10 | 2018 | 211 | |
| 11 | HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor–Mutated Non–Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy Hit paper breakdown → | 2023 | 188 |
| 12 | 2009 | 178 | |
| 13 | 2009 | 175 | |
| 14 | 2014 | 156 | |
| 15 | 2019 | 152 | |
| 16 | 2017 | 150 | |
| 17 | 2021 | 150 | |
| 18 | 2010 | 149 | |
| 19 | 2013 | 146 | |
| 20 | ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer Hit paper breakdown → | 2022 | 144 |
About Tom John
Tom John is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Cancer Research, Immunology and Ophthalmology, having authored 257 papers that have together received 14.3k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (91 papers), Cancer Immunotherapy and Biomarkers (42 papers), Lung Cancer Research Studies (28 papers), Cancer Genomics and Diagnostics (28 papers), Occupational and environmental lung diseases (24 papers), Colorectal Cancer Treatments and Studies (23 papers), Lung Cancer Diagnosis and Treatment (21 papers) and Immunotherapy and Immune Responses (17 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (7.8k citations), Oncology (5.9k citations), Cancer Research (1.9k citations), Ophthalmology (395 citations) and Pathology and Forensic Medicine (765 citations). Tom John has collaborated with scholars based in Australia, United States and United Kingdom. Frequent co-authors include Frances Alice Shepherd, Alexander Dobrovic, Puey Ling Chia, Ming‐Sound Tsao, Suresh S. Ramalingam, Geoffrey Liu, Paul Leslie Ross Mitchell, Yi-Long Lung Cancer Wu, Yuri Rukazenkov and James Chih‐Hsin Yang. Their work appears in journals such as Journal of Thoracic Oncology, Annals of Oncology, Lung Cancer, Translational Lung Cancer Research and Journal of Clinical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.